Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

RIVAROXABAN CRS (110 MG)

RIVAROXABAN CRS (110 MG)

366789-02-8

DISCOVER
RIVAROXABAN IMPURITY A CRS (5MG)

RIVAROXABAN IMPURITY A CRS (5MG)

ND

DISCOVER
LATANOPROST FOR SYSTEM SUITABILITY CRS (2 MG)

LATANOPROST FOR SYSTEM SUITABILITY CRS (2 MG)

ND

DISCOVER
GANODERIC ACID A CRS (20 MG)

GANODERIC ACID A CRS (20 MG)

ND

DISCOVER
VITEXIN-2"-O-RHAMNOSIDE CRS (10 MG)

VITEXIN-2"-O-RHAMNOSIDE CRS (10 MG)

ND

DISCOVER
AMPROLIUM HYDROCHLORIDE CRS (50 MG)

AMPROLIUM HYDROCHLORIDE CRS (50 MG)

ND

DISCOVER
RIVAROXABAN FOR SYSTEM SUITABILITY CRS (15 MG)

RIVAROXABAN FOR SYSTEM SUITABILITY CRS (15 MG)

NA

DISCOVER
PENTOBARBITAL SODIUM CRS - * PSY (40 MG)

PENTOBARBITAL SODIUM CRS - * PSY (40 MG)

ND

DISCOVER
DEFERASIROX IMPURITY F CRS (20 MG)

DEFERASIROX IMPURITY F CRS (20 MG)

ND

DISCOVER
DEFERASIROX CRS (70 MG)

DEFERASIROX CRS (70 MG)

ND

DISCOVER
DEFERASIROX FOR SYSTEM SUITABILITY CRS (10 MG)

DEFERASIROX FOR SYSTEM SUITABILITY CRS (10 MG)

ND

DISCOVER
DEFERASIROX IMPURITY B CRS (15 MG)

DEFERASIROX IMPURITY B CRS (15 MG)

ND

DISCOVER